Please ensure Javascript is enabled for purposes of website accessibility

Novavax Launches Midstage Coronavirus Vaccine Trial

By Jim Crumly – Aug 17, 2020 at 1:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The trial will be conducted in South Africa, which is experiencing a winter surge of COVID-19.

Vaccine specialist Novavax (NVAX -10.14%) announced the launch of a phase 2b clinical trial in South Africa to test the effectiveness of its coronavirus vaccine, NVX-CoV2373. The trial is an opportunity for the company to test the vaccine in an environment where the pandemic is surging during the cold weather of winter. South Africa has had more than half the COVID-19 cases on the African continent.

Vial of coronavirus vaccine.

Image source: Getty Images.

Novavax's vaccine consists of an antigen derived from the coronavirus spike protein plus a proprietary adjuvant, an ingredient that boosts the body's immune response. The company released phase 1 data from a phase 1/2 trial of the vaccine on August 8, which showed that NVX-CoV2373 produced antibodies to the virus numerically superior to levels found in patients who have recovered from the disease. The phase 2 portion of that trial will begin with about 1,500 adults in the U.S. and Australia this month. The phase 2b test announced today will enroll about 2,665 healthy adults and about 240 medically stable, HIV-positive adults.

Novavax is somewhat behind the leaders in the race for an approved vaccine for COVID-19, but the level of transmission in South Africa may give the company a chance to evaluate the efficacy of its vaccine very quickly. The company has also already lined up manufacturing capacity for over 2 billion doses.  

Jim Crumly has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$18.87 (-10.14%) $-2.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.